Cytokinetics Beheer

Beheer criteriumcontroles 2/4

De CEO Cytokinetics is Robert Blum, benoemd in Feb2006, heeft een ambtstermijn van 18.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.75M, bestaande uit 9% salaris en 91% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde € 12.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 11.8 jaar.

Belangrijke informatie

Robert Blum

Algemeen directeur

US$8.8m

Totale compensatie

Percentage CEO-salaris	9.0%
Dienstverband CEO	18.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	11.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Robert Blum's beloning veranderd ten opzichte van Cytokinetics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$576m
Jun 30 2024	n/a	n/a	-US$545m
Mar 31 2024	n/a	n/a	-US$531m
Dec 31 2023	US$9m	US$790k	-US$526m
Sep 30 2023	n/a	n/a	-US$527m
Jun 30 2023	n/a	n/a	-US$540m
Mar 31 2023	n/a	n/a	-US$431m
Dec 31 2022	US$9m	US$742k	-US$389m
Sep 30 2022	n/a	n/a	-US$282m
Jun 30 2022	n/a	n/a	-US$216m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$6m	US$709k	-US$215m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$156m
Mar 31 2021	n/a	n/a	-US$135m
Dec 31 2020	US$5m	US$682k	-US$127m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$140m
Mar 31 2020	n/a	n/a	-US$132m
Dec 31 2019	US$3m	US$656k	-US$122m
Sep 30 2019	n/a	n/a	-US$118m
Jun 30 2019	n/a	n/a	-US$110m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$3m	US$630k	-US$106m
Sep 30 2018	n/a	n/a	-US$120m
Jun 30 2018	n/a	n/a	-US$131m
Mar 31 2018	n/a	n/a	-US$132m
Dec 31 2017	US$3m	US$612k	-US$128m

Compensatie versus markt: De totale vergoeding ($USD 8.75M ) Robert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 3.59M ).

Compensatie versus inkomsten: De vergoeding van Robert is gestegen terwijl het bedrijf verliesgevend is.

CEO

Robert Blum (60 yo)

18.8yrs

Tenure

US$8,751,057

Compensatie

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Blum	CEO, President & Director	18.8yrs	US$8.75m	0.23% € 12.9m
Robert Wong	VP & Chief Accounting Officer	5.5yrs	US$1.04m	0.0063% € 352.2k
Fady Malik	Executive Vice President of Research & Development	12.4yrs	US$4.44m	0.053% € 2.9m
Andrew Callos	Executive VP & Chief Commercial Officer	3.7yrs	US$3.20m	0.021% € 1.2m
James Spudich	Co-Founder & Member of Scientific Advisory Board	27.3yrs	US$21.94k	geen gegevens
Sung Lee	Executive VP & CFO	less than a year	geen gegevens	geen gegevens
Jeff Lotz	Vice President of Sales & Operations	3.2yrs	geen gegevens	geen gegevens
Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	less than a year	geen gegevens	geen gegevens
Steven Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	no data	geen gegevens	geen gegevens
Kari Loeser	VP & Chief Compliance Officer	3yrs	geen gegevens	geen gegevens
John Faurescu	VP, Associate General Counsel & Corporate Secretary	no data	geen gegevens	geen gegevens
Scott Jordan	Senior Vice President of Global Marketing & Commercial Strategy	3.5yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KK3A wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Blum	CEO, President & Director	17.8yrs	US$8.75m	0.23% € 12.9m
James Spudich	Co-Founder & Member of Scientific Advisory Board	no data	US$21.94k	geen gegevens
B. Parshall	Independent Director	11.8yrs	US$529.02k	0.013% € 707.2k
James H. Sabry	Co-Founder & Chairman of Scientific Advisory Board	16.6yrs	US$41.50k	geen gegevens
Nancy Wysenski	Independent Director	4yrs	US$519.02k	0.015% € 819.6k
John Henderson	Independent Chairman	15.8yrs	US$559.02k	0.028% € 1.6m
John Lowe	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Thomas Pollard	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Morgans	Member of Scientific Advisory Board	8.3yrs	US$942.23k	geen gegevens
Lawrence S. Goldstein	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Solaro	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Muna Bhanji	Independent Director	3.8yrs	US$509.02k	0.010% € 567.0k

11.8yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KK3A zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

Cytokinetics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently sold €580k worth of stock

CEO, President & Director recently sold €1.1m worth of stock

VP & Chief Accounting Officer recently sold €584k worth of stock

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Recent updates

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089

New major risk - Negative shareholders equity

Third quarter 2024 earnings released: US$1.36 loss per share (vs US$1.35 loss in 3Q 2023)

Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024

Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions

Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$1.34 loss in 2Q 2023)

New minor risk - Share price stability

Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024

CEO, President & Director recently sold €580k worth of stock

CEO, President & Director recently sold €1.1m worth of stock

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

New minor risk - Share price stability

VP & Chief Accounting Officer recently sold €584k worth of stock

New minor risk - Insider selling

Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

First quarter 2024 earnings released: US$1.33 loss per share (vs US$1.38 loss in 1Q 2023)

Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings released: US$5.45 loss per share (vs US$4.33 loss in FY 2022)

New major risk - Revenue and earnings growth

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

Now 20% undervalued

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Insufficient new directors

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.35 loss per share (vs US$1.52 loss in 3Q 2022)

Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023

Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

New minor risk - Share price stability

Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society

Second quarter 2023 earnings released: US$1.34 loss per share (vs US$0.23 loss in 2Q 2022)

Cytokinetics, Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Cytokinetics, Incorporated Presents New Data in Patients with Non-Obstructive Hcm from Cohort 4 of Redwood-Hcm in Late-Breaking Clinical Trial Session At the European Society of Cardiology Heart Failure 2023 Congress

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4021586

First quarter 2023 earnings released: US$1.38 loss per share (vs US$1.05 loss in 1Q 2022)

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2022 earnings released: US$4.33 loss per share (vs US$2.80 loss in FY 2021)

Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023

Cytokinetics, Incorporated Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

VP & Chief Accounting Officer recently sold €83k worth of stock

Cytokinetics, Incorporated Presents New Data at the American Heart Association Scientific Sessions 2022

Third quarter 2022 earnings released: US$1.52 loss per share (vs US$0.95 loss in 3Q 2021)

Cytokinetics, Incorporated to Report Q3, 2022 Results on Nov 03, 2022

Cytokinetics, Incorporated Announces Continuation of COURAGE-ALS Following First Interim Analysis

Cytokinetics, Incorporated Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.86 loss in 2Q 2021)

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics' Completed ALS Clinical Trials

Cytokinetics, Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Cytokinetics, Incorporated Provides Update on New Drug Application

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions

First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.66 loss in 1Q 2021)